BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life sciences and biotechnology sectors, with a proven track record of driving growth and innovation across global markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240916598040/en/

Armin Spura, PhD, CEO, BioDuro-Sundia (Photo: Business Wire)

Dr. Spura joins BioDuro-Sundia from Crown Bioscience, where he served as the CEO for nearly five years, guiding the company through significant growth and strategic development. Throughout his career, Dr. Spura has held senior leadership positions at several well-known organizations such as Thermo Fisher Scientific, WuXi NEXTCODE, CareDx and Ion Torrent. He also holds various advisory roles, serving as the chair of the board of directors for SeromYx Systems and as a life science investment advisor at K2X Technology and Life Science.

Early in his career, Dr. Spura helped to grow two start-up companies: Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Dr. Spura studied biochemistry in Germany and received his Ph.D. in molecular biology from Brown University in the US.

“I am honored to join BioDuro-Sundia and lead this talented team as we embark on the next phase of growth,” said Dr. Spura. “With our unique, fully integrated CRDMO platform — encompassing chemistry, biology, DMPK, drug substance, and drug product from discovery through to commercial manufacturing — I am confident we will empower more partners to bring better treatments to patients around the world faster.”

Gary Chu, Chairman of the Executive Operation Committee of the company, added, “Dr. Spura’s extensive global experience and visionary leadership is instrumental in driving BioDuro-Sundia's accelerated growth. We are excited and confident that under his leadership, we will continue to innovate and deliver integrated solutions that meet growing needs from our clients worldwide and the broader healthcare community.”

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company, is a CRDMO with a 28-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, with over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, DMPK, drug substance, and drug product.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240916598040/en/

Christina Coby
Marketing Manager
christina.coby@bioduro-sundia.com

Logo

Images

Tags

More Like This

/C O R R E C T I O N -- Suanfarma/

Curia Appoints Gerald Auer as Chief Financial Officer

BioCina and NovaCina Merger Bolsters Global CDMO Industry

Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.

Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Accelerate Global Commercial Expansion

Brenus Pharma Strengthens Its Governance With Designation of a New President and Appointment of Former Novo Nordisk EVP as Independent Member

Duality Bio Appoints Hua Mu as Global Chief Medical Officer

Hansa Biopharma announces key executive appointments to support continued growth